Receptor for Advanced Glycation End products (RAGE) has been implicated in amyloid b-peptide (Ab)-induced perturbation relevant to the pathogenesis of Alzheimer's disease (AD). However, whether and how RAGE regulates Ab metabolism remains largely unknown. Ab formation arises from aberrant cleavage of amyloid pre-cursor protein (APP) by b-and c-secretase. To investigate whether RAGE modulates b-and c-secretase activity potentiating Ab formation, we generated mAPP mice with genetic deletion of RAGE (mAPP/RO). These mice displayed reduced cerebral amyloid pathology, inhibited aberrant APP-Ab metabolism by reducing b-and c-secretases activity, and attenuated impairment of learning and memory compared with mAPP mice. Similarly, RAGE signal transduction deficient mAPP mice (mAPP/DN-RAGE) exhibited the reduction in Ab40 and Ab42 production and decreased b-and c-secretase activity compared with mAPP mice. Furthermore, RAGE-deficient mAPP brain revealed suppression of activation of p38 MAP kinase and glycogen synthase kinase 3b (GSK3b). Finally, RAGE siRNAmediated gene silencing or DN-RAGE-mediated signaling deficiency in the enriched human APP neuronal cells demonstrated suppression of activation of GSK3b, accompanied with reduction in Ab levels and decrease in b-and c-secretases activity. Our findings highlight that RAGE-dependent signaling pathway regulates b-and c-secretase cleavage of APP to generate Ab, at least in part through activation of GSK3b and p38 MAP kinase. RAGE is a potential therapeutic target to limit aberrant APP-Ab metabolism in halting progression of AD.
Introduction
Cerebral amyloid plaques are characteristic lesions found in Alzheimer's disease (AD) and are composed of amyloid-b (Ab) peptide, including Ab1-40 and Ab1-42, which are the endoproteolytic derivatives from amyloid pre-cursor protein (APP) (1) . Ab formation involves sequential cleavage of APP by proteolytic reactions of b-and c-secretase (2) (3) (4) (5) . b-Secretase mediates APP cleavage to form the amino (N)-terminus of Ab and yield the membrane bound C-terminal fragment CTFb (3) . Next, c-secretase cleaves CTFb to release Ab peptide and APP intracellular Cterminal domain (AICD), a 6-KD peptide also called CTFc (4) . Excessive Ab production, aggregation, and deposition arise from aberrant APP metabolism that is thought to be an underlying cause of neurodegenerative outcomes in AD. Given that the accumulation of aggregated Ab is associated with AD progression and both b-and c-secretase are pre-requisite for APP processing to generate Ab, much work have focused on choosing either or both of these proteases as prime drug targets aim to lower Ab levels in halting AD progression. Several drugs exerted modifying or controlling influences on the activity of these secretases, but they have failed in clinical trials due to severe side effects or to difficulty in delivery through the blood brain barrier (6) (7) (8) (9) . Hence, the successful treatments that address the mechanism of modulation of either or both of these APP processing enzymes in Ab formation remain elusive.
The Receptor for Advanced Glycation of End products (RAGE) is a multiligand member of the immunoglobulin superfamily and functions as a cell surface receptor for Ab (10) (11) (12) (13) . Multiple lines of evidence indicate that RAGE is an important cellular cofactor for Ab-mediated perturbation relevant to the pathogenesis of AD. Investigation of human brains revealed higher levels of RAGE expression in neuronal, microglial and endothelial cells in patients with AD compared with age-matched, nondemented controls (14) (15) (16) (17) (18) . Expression levels of RAGE are correlated to the severity of the disease indicated by clinical score of the amyloid plaque or tangle (15) . Our previous studies on a transgenic mouse model demonstrated elevated expression of RAGE in mice with targeted neuronal overexpression of a mutant form of human APP (mAPP) and increased levels of RAGE in the neurons and microglia of these mice as they age and accumulate Ab (19, 20) . Overexpression of RAGE in neurons or microglia of mAPP mice displayed accelerated accumulation of Ab and exacerbated spatial learning/memory impairment, neuropathological and biochemical changes compared with mAPP mice alone (19, 20) . On the other hand, introduction of DN-RAGE, signal transduction-deficient mutants of RAGE, into neurons or microglia of mAPP mice exhibited attenuation of Abinduced deterioration and displayed preservation of spatial learning/memory and protection against synaptic dysfunction (19) (20) (21) (22) . These observations suggest that changes of RAGE expression levels might influence the Ab-induced cellular perturbation relevant to the development and progression of AD. However, the mechanisms of involvement of RAGE in APP processing and Ab formation have not been elucidated. Additionally, it is unclear whether lack of RAGE would afford protection against cerebral Ab accumulation and deficits in learning memory in an AD mouse model.
Here, we extended follow-up to our prior studies on the detrimental effects of RAGE-Ab interaction in AD in order to deepen our comprehensive understanding of the following new questions: 1) Does blockade of RAGE reduce cerebral Ab accumulation and amyloid pathology together with improvement in cognition? 2) Does RAGE modulate APP processing and subsequent Ab production? 3) If it does, is RAGE-dependent or independent signaling pathway responsible for activation of b-or c-secretase? Finally, what may another molecules be involved in this signaling cascade? We generated mAPP mice with genetic deficiency of RAGE (mAPP/RO) and used our previously produced mAPP/DN-RAGE mice targeted to neurons (19) , as well as rat neuroblastoma B103-wtAPP cells stably expressing human wild-type (WT) APP (23) to address these key questions. We demonstrated for the first time that deletion or blockade of RAGE or signal transduction-deficient mutants of RAGE confers striking protection from abnormal APP processing and Ab accumulation. We provided evidence that RAGE-dependent signaling pathway regulates b-and c-secretase cleavage of APP to generate Ab, at least in part via activation of glycogen synthase kinase 3b (GSK3b) and p38 MAP kinase.
Results

Effects of RAGE deficiency on Ab accumulation and b and c secretase activity in mAPP mice
In view of elevated expression of RAGE correlated to the severity of Ab accumulation in AD patients and AD mouse model (14) (15) (16) (17) (18) (19) (20) , we sought to detect the causative effect of RAGE on APP processing and Ab production by deletion of RAGE in mAPP mice, a well-established animal model for AD. Homozygous RAGE null mice (here termed as RO mice) were crossed with mAPP mice overexpressing mutant APP/Ab to generate mAPP/ RO mice. We demonstrated that RAGE protein levels were significantly elevated in mAPP mice compared with WT mice (Supplementary Material, Fig. S1 ). In contrast, RAGE expression was blocked in either mAPP/RO or RO mice due to globally genetic deletion of RAGE (Supplementary Material, Fig. S1 ). Measurement of Ab by ELISA revealed significantly reduced Ab40 and Ab42 levels in the brains of mAPP/RO mice compared with mAPP mice at 12 months of age ( Fig. 1A and B) . Consistent with these results, quantification of Ab plaque loads revealed that the area occupied by Ab deposits in cerebral cortex of mAPP/RO mice was significantly decreased compared with those of mAPP mice at 12 months of age ( Fig. 1C and D) . Since Ab is generated from sequential cleavage of APP by b-and c-secretases, we next examined the effect of RAGE deficiency on APP processing to provide evidence for these two enzyme activities. We performed an in vitro cleavage assay, followed by Western blotting to detect the fragments of CTFb (11 KD) and CTFc (6 KD) arisen from b-or c-secretase cleavage of full-length APP that are the indexes of b-and c-secretase activity, respectively. Notably, the intensity of immunoreactive bands migrating at $11 KD and 6 KD corresponding to CTFb ($11 KD) and CTFc ($6 KD), was significantly reduced by 60% and 50% in mAPP/RO mice, respectively, compared with mAPP mice at 12 months of age ( Fig. 1E-G) . In parallel, levels of beta-secretase 1 (BACE1), also known as beta-site APP cleaving enzyme 1, was significantly increased in mAPP mouse cortex compared with WT mice, however, it was dramatically reduced in mAPP/RO mice (Fig. 1H) . The results of reduced yields of CTFb and CTFc as well as decreased BACE1 enzyme in mAPP/RO mice provided the solid evidence that both b-and c-secretase activities were significantly diminished in mAPP/RO mice compared with mAPP mice. Measurement of endogenous mouse APP in the brain of the four groups of mice (mAPP, mAPP/RO, RO and WT) showed no differences (Fig. 1I ). In addition, there are no differences for human APP in mAPP and mAPP/RO mice (Fig. 1J) , suggesting that loss of RAGE does not affect APP production. Thus, ablation of RAGE contributes to mitigation of aberrant APP processing and Ab accumulation via reduction of b-and c-secretase activity in an AD mouse model.
Effect of RAGE-deficient cytosolic domain in neurons on Ab production and b-and c-secretase activity in mAPP mice Next, we determined whether RAGE had a direct role in transducing signal molecules important for APP cleavage and Ab production in an Ab rich environment by employing mAPP/DN-RAGE mice expressing neuronal RAGE-deficient cytosolic domain responsible for RAGE-mediated signal transduction (19) . Consistent with our observations on mAPP/RO mice, Ab40 ( Fig. 2A) and Ab42 (Fig. 2B ) levels were significantly reduced in the hippocampus homogenates of mAPP/DN-RAGE mice compared with mAPP mice at 10 months of age. The intensity of immunoreactive bands for the fragments of CTFb and CTFc generated by b-or c-secretase cleavage of APP was significantly decreased in mAPP/DN-RAGE mice compared with mAPP mice (Fig. 2C) . Accordingly, the intensities of immunoreactive bands for CTFb and CTFc were significantly reduced in mAPP/DN-RAGE mice compared with mAPP mice. These data suggest that cytosolic domain of neuronal RAGE signaling is responsible for aberrant APP processing and Ab production through magnification of b-and c-secretase activity in an AD mouse model.
Silencing RAGE gene diminished Ab production by decreasing b-and c-secretase activity in human APP/Ab-producing neuronal cells in vitro
To delineate the mechanism underlying the impact of RAGE on regulation of b-and c-secretase activity, we used rat neuroblastoma B103-wtAPP cells, which stably expressed human APP and were characterized by increase in Ab fragment production as our in vitro model. B103-wtAPP cells were transfected with RAGE siRNA to suppress RAGE expression, and then were assessed for Ab production and activities of b and c secretases. First we demonstrated that RAGE mRNA expression by real time quantitative PCR analysis was greatly reduced by $80% in B103-wtAPP cells transfected with RAGE siRNA compared with the cells with treatment of non-siRNA or negative control siRNA (Fig. 3A) , confirming that RAGE expression was efficiently knockdown by RAGE-siRNA. To investigate Ab production in RAGE siRNA transfected B103-wtAPP cells, we examined Ab42 levels in the media and cell lysis of B103-wtAPP cells by ELISA. Knockdown of RAGE by siRNA produced a striking reduction of Ab42 levels in the media compared with the cells treated with non-siRNA or negative control siRNA (Fig. 3B) . Similarly, Ab42 levels were decreased in the cell lysates of B103-wtAPP cells transfected with RAGE siRNA compared with the cells treated with non-siRNA or negative control siRNA (Fig. 3C ). However, Western blot analysis of APP revealed no change in APP cellular level in B103-wtAPP cells after siRNA knockdown of RAGE ( Fig. 3D and F) . To further investigate the effect of knockdown of RAGE on APP cleavage, B103-wtAPP cells transfected with RAGE siRNA were harvested for assessments of b-and csecretase activity. We observed that yields of the fragments of CTFb and CTFc were significantly lower in RAGE siRNA transfected B103-wtAPP cells compared with non-siRNA or negative control siRNA transfected cells ( Fig. 3E and F) , indicating a link of RAGE to APP processing by modulation of both b-and c-secretase. The negative control siRNA did neither affect APP processing nor alter Ab levels. These results confirmed specific effects of siRNA knockdown of RAGE gene expression on APP processing and Ab levels in our experiments. These data suggest that blockage of RAGE reduces b-and c-secretase cleavage of fulllength APP to release Ab.
Effect of blockade of RAGE-dependent intracellular signaling on Ab production and b-and c-secretase activity in human APP/Ab producing neuronal cells
To further determine the contribution of RAGE-dependent signaling to Ab production and APP processing, B103-wtAPP cells were transfected with a DN-RAGE construct. DN-RAGE comprises the extracellular and membrane-spanning domains of RAGE, but lacks the cytosolic tail, which has previously been shown to block RAGE-dependent intracellular signaling mechanism in vivo (19, 20) . In vitro analyses, we assessed Ab production, b-and c-secretase activity in the above cells. Blockade of RAGEdependent intracellular signaling in B103-wtAPP cells with DN-RAGE transfection produced a significant reduction of Ab42 in the media compared with pcDNA3 transfection (Fig. 4A) . Accordingly, b-and c-secretase activity was significantly decreased in DN-RAGE transfected groups compared with pcDNA3 vector transfected groups as evidence by reduction of intensity of immunoreactive bands for these enzymes' decomposition products CTFb and CTFc from the full-length of APP ( Fig. 4B and D ). There were no differences in full length APP in B103-wtAPP cells transfected with DN-RAGE and pcDNA3 ( Fig. 4C and D) . These data indicate the contribution of RAGE signaling to abnormal APP processing in Ab milieu. Blockade of RAGE-dependent signaling limits Ab production by inhibiting activity of b-and c-secretase, without interfering with APP generation/production.
Effects of RAGE deficiency on activation of GSK3b and p38 signaling pathway in mAPP mice RAGE functions as a signal transduction receptor, which activates multiple downstream intracellular pathways, including p38 MAP kinase and GSK3 in different disease settings (19, 20, 22, (24) (25) (26) (27) . Thus, we sought to determine if RAGE mediated cellular activation of such intracellular mechanisms, which might have impact on Ab production in mAPP mice. Given that GSK3 is a serine/threonine protein kinase and phosphorylation via serine 9 (Ser 9) in the b-isoform inhibits GSK3 activity (28), we tested the phosphorylation of GSK3b (Ser 9) in the indicated groups. Assessment of the phosphorylation levels of GSK3b (Ser 9) revealed a significant lower in mAPP mice than WT control mice at 4 months of age, indicating GSK3b pathway was activated in mAPP mice (Fig. 5A ). However, compared with mAPP mice, the increased phosphorylation of GSK3b (Ser 9) leading to its inactivation was observed in mAPP/RO mice ( Fig. 5A ), indicating that inactivation of GSK3b was evident in mAPP mice devoid of RAGE. Given the involvement of RAGE in Ab-mediated activation of p38 MAP kinase in cultured cortical neurons (25) and neuronal and microglial RAGE overexpressing mAPP mice (19, 20) , we next determined whether phosphorylated p38 levels were altered in vivo Ab-enriched environment. Indeed, phosphorylation of p38 was elevated in mAPP mice compared with WT mice at 4 months of age (Fig. 5B ), which were consistent with our published observations (19, 20) . Importantly, RAGE-deficient mAPP mice displayed reduction in phosphorylated p38 MAP kinase levels compared with that in mAPP mice (Fig. 5B ). These data demonstrated that lack of RAGE blocks the activation of GSK3b and p38 MAPK signaling pathway in Ab milieu of mAPP mice.
Effect of inhibition of GSK3b on Ab production and b-and c-secretase activity in human APP/Ab producing neuronal cells
To further determine if RAGE deficiency contributes to lower Ab production and b-and c-secretase activity via blockade of activation of GSK3b, lithium chloride (LiCl), a selective inhibitor targeting the inhibitory phosphorylation site of GSK3b (Ser 9), was applied to B103-wtAPP cells. The cells treated with LiCl for 48 h displayed increased phosphorylation of GSK3b (Ser 9) (P-GSK3b) in a dose-dependent manner (Fig. 6A ), but without changes in total-GSK3b (T-GSK3b), indicating dose-dependent inhibition of GSK3b activity. Interestingly, addition of SB203580 (1 mM), a specific inhibitor of p38 significantly inhibited GSK3b activation as shown by increased phosphorylated GSK3b (Ser 9) (Fig. 6B) . Importantly, similar inhibitory effect on GSK3b activation was observed in DN-RAGE-or RAGE siRNA-transfected B103-wtAPP cells as demonstrated by a significant increase in phosphorylated GSK3b (Ser 9) in DN-RAGE-or RAGE siRNA-transfected B103-wtAPP cells as compared with those control cells transfected with vector or negative control siRNA ( Fig. 6C and D) . These results provide evidence that blockade or selective deficiency of RAGE signaling or inhibition of p38 phosphorylation hampers activation of GSK3b. Analogous to RAGE siRNA interference, treatment of LiCl (1 mM) for 48 h, which is able to inhibit GSK3b activity with reduction by 50%, induced significant decrease of Ab42 production in the medium and cell lysis of B103-wtAPP cells compared with non-treated cells (Fig. 6E and F) . In parallel, the intensity of immunoreactive bands for CTFb and CTFc fragments were attenuated dramatically in B103-wtAPP cells in the presence of LiCl (1 mM) compared with the absence of LiCl (Fig. 6G) , indicating that both b-and c-secretase activities were significantly decreased by inhibition of GSK3b activity. These findings suggest that GSK3b is a downstream target of p38 and RAGE and its activation plays an important role in regulation of b-and c-secretase activity in the aberrant APP-Ab metabolism.
Effect of RAGE deficiency on spatial learning/memory in mAPP mice
Give that progressive deterioration of memory is commonly the presenting complaint in AD, and in view of the early abnormalities of spatial learning/memory in mAPP/RAGE mice overexpressing neuronal or macroglial RAGE but preservation of learning and memory in mAPP/DN-RAGE mice expressing neuronal or microglial signal transduction deficient mutant RAGE compared with mAPP mice (19, 20) , we investigated whether deletion of RAGE would improve spatial learning and memory in AD mouse model. We evaluated spatial/learning and memory abilities by the radial arm water maze test in mAPP, mAPP/RO, RO mice, and WT littermates. At 12 months of age, mAPP/RO mice displayed significant improvement of spatial learning and memory ($2.5-3 errors by trials 3 and 4 and retention test) compared with mAPP mice ($4-5 errors by trials 3 and 4 and retention test; Fig. 7A ). RO mice did not exhibit abnormal behavior compared with WT mice ($2 errors by trials 3 and 4 and retention test). In addition, we also tested mice with a visible platform task to control for motor, sensorial and motivational defects that might have interfered with assessment of mouse behavior during cognitive testing. The four genotypes showed no difference in their latency time and speed to reach the platform and latency to the platform during the visible platform sessions (Fig. 7B and C) . These data suggest that RAGE deficiency exerts protective effect on deficits in learning and memory in mice overexpressing mutated APP.
Discussion
Although several important signaling pathways have potential to affect APP proteolysis, we have focused our attention on RAGE-signaling pathway. Our previous studies demonstrated that increased cellular RAGE renders more vulnerable to Abmediated perturbation in patients of AD and in an AD mouse model (15, 19, 20) . However, selective deficiency of neuronal or microglial RAGE signaling by DN-RAGE in the AD mouse model attenuated deterioration induced by Ab (19) (20) (21) (22) . Thus, the current study was designed to evaluate whether global deletion of RAGE would have protective effects against Ab accumulation, amyloid pathology and learning and memory deficits and to elucidate the mechanism by which RAGE regulates b-and c-secretase activity responsible for cleavage of APP to release Ab. We developed a genetically modified mouse model (mAPP/RO mice) with deficiency of RAGE (29) in an Ab-rich environment provided by a transgene for mutant APP/Ab driven by the PDGF Bchain promoter (30) . We demonstrated for the first time that mAPP/RO mice displayed reduced cerebral amyloidosis, inhibited aberrant APP-Ab metabolism by reducing b-and c-secretases activity shown as lower yield of CTFb and CTFc and less BACE1 enzyme, and attenuated impairment of learning and Figure 5 . Effect of RAGE deficiency on phosphorylation of GSK3b and p38 MAPK in mAPP mice. The levels of phosphorylated GSK3b at Ser-9 (P-GSK3b) (A) and phosphorylated p38 MAPK (B) in the mouse brain homogenates from indicated four genotypes were measured by ELISA. The bar graphs show fold increase in phosphorylated GSK3b (A) and phosphorylated p38 MAPK (B), respectively in the brain homogenates from indicated mice. N ¼ 4-7 mice per group. *P < 0.01 mAPP versus WT mice or RO mice; # P < 0.05 mAPP/RO versus mAPP mice.
memory compared with mAPP mice at 12 months of age. Importantly, mAPP/DN-RAGE mice expressing neuronal signal transduction deficient mutant RAGE exhibited reduced Ab40 and Ab42 production and decreased b-and c-secretase activity compared with mAPP mice. Further studies on elucidating the potential signal transduction pathways revealed that p38 MAP kinase signaling was significantly down-regulated in the brain of APP/RO mice, and that phosphorylation of GSK3b (Ser 9) was increased in the brain of mAPP/RO mice indicating decreased GSK3b activity by deletion of RAGE, compared with APP mice at early stage 4 months of age. Therefore, we consider these two pathways as downstream signaling cascades triggered by RAGE that contribute to the early phases of AD based on that activation of p38 MAP kinase and GSK3b was detected in mAPP mice at young age, well before the onset of extensive extracellular Ab accumulation. Furthermore, suppression of GSK3b activation, inhibition of b-and c-secretase activity and decrease in Ab formation by knockdown/blockade of RAGE expression or RAGEdependent intracellular signaling with RAGE-siRNA/DN-RAGE in the enriched human APP/Ab neuronal cells provided concrete evidence that RAGE-mediated Ab formation via GSK3b signaling pathway. The four genotypes showed no difference in their latency time (B) and speed (C) to reach the platform during the visible platform session.
Mounting evidence supports that p38 MAP kinase signaling cascade contributes to cytokine overproduction and neurodegenerative effects seen in AD (20, 24, (31) (32) (33) . Activation of p38 MAP kinase was found in early AD brain and in an AD mouse model, while inhibition of p38 MAP kinase activation blocks Ab-mediated cytokine production and neuronal death (19, 20, 24, (34) (35) (36) . Our previous studies demonstrated that phosphorylated of p38 levels were significantly increased in mAPP mice compared with WT controls, further, mAPP/RAGE with overexpression of neuronal or microglial RAGE displayed even higher levels of phosphorylated p38 than mAPP mice, whereas mAPP/DN-RAGE exhibited less p38 phosphorylation compared with mAPP mice (19, 20) . These indicate that existence of RAGE-dependent activation of p38 MAP kinase in neurons and microglia contributes to Ab-involved neuronal inflammation and neuronal injury. In the current study, we further demonstrated that deficiency of RAGE in mAPP mice significantly mitigated p38 MAP kinase signaling pathway activation accompanying with reduced b-and c-secretase activity and decreased Ab production compared with mAPP mice.
RAGE was first identified and characterized as a signal transduction receptor for AGEs (37, 38) . Methylglyoxal (MG) induced AGEs formation has been reported involving RAGE upregulation and GSK3b activation (27) . MG-AGE-induced cardiomyocyte dysfunction was associated with reduced GSK3b inactivation as shown loss of GSK3b (Ser 9) phosphorylation and treatment with RAGE siRNA blocked diabetes-induced GSK3b activation (39) . However, involvement of RAGE signaling in regulation of GSK3b activity has not been reported in Ab-mediated perturbation in AD. GSK3 is widely expressed in all tissues, with particularly abundant levels in brain (40) . The widespread expression of GSK3b in the adult brain suggests a fundamental role for GSK3b in neuronal signaling pathways (41) . GSK3b has been demonstrated to play an important role in neuronal cell death (42) . It has been reported that the neurotoxic effect of Ab42 is mediated by GSK3b activation, and that inhibition of GSK3b activity can reduce Ab42-induced neurotoxicity (42) , and optimized inhibitor level for modulating GSK3b activity may prevent apoptosis induced by oxidative stress associated with neurodegenerative diseases (43) . LiCl, a selective inhibitor targeting the inhibitory phosphorylation site of GSK3b (Ser 9), was shown to cause a large increase in the phosphorylation of GSK3b (Ser 9) in vivo (44), and to protect neurons from apoptosis by inhibiting the activity of GSK3b (45) . Specific inhibition of cellular GSK3 by lithium elicits a reduction in Ab. Indeed, our current results of B103-wtAPP cells showed that LiCl inhibited GSK3b activity in a dose dependent manner with a maximum reduction by 50% and induced significant decrease of Ab40 and Ab42 production. Consistent with our observations, lithium inhibited Ab production was reported in HEK293 cells stably transfected with Swedish (APP)(751) and in the brains of the PDAPP (APP(V717F)) AD transgenic mice (46) . Oral administration of lithium abolished GSK3b-mediated Ab increase in the brains of GSK3b transgenic mice and reduced Ab plaques burden in the brains of the PDAPP (APP(V717F)) transgenic mice (46) . These observations demonstrated that altered GSK3b activity influenced Ab production levels, suggesting that GSK3b is a potential downstream kinase involved in APP processing. However, these studies lacked the mechanism underlying GSK3b regulation of APP processing. We provided the evidence that inhibition of GSK3b activity in B103-wt APP cells by LiCl significantly attenuated b-and c-secretase activity as shown lower yield of their cleavage products CTFb and CTFc, indicating that b-and c-secretase is downstream target of GSK3b. Notably, we further demonstrated that deletion of RAGE or neuronal signal transduction deficient mutant RAGE (DN-RAGE) in mAPP mice, or knockdown/blockade of RAGE in B103-wtAPP cells by RAGEsiRNA/DN-RAGE significantly inhibited GSK3b activity accompanying with reduced b-and c-secretase activity and decreased Ab production. Our findings indicate that RAGE-dependent signal transduction in GSK3b activation is an important mechanism underlying b-and c-secretase involved cleavage of APP to generate Ab (Fig. 8) . Moreover, we found that inhibition of p38 phosphorylation significantly suppressed activation of GSK3b, suggesting that GSK3b might be a downstream target of p38 (Fig. 8) .
Pharmacological intervention in b-and c-secretase activity has been heavily investigated for over a decade to prevent the buildup of the amyloid plaques and the formation of toxic amyloid dimmers and oligomers (47) . On the basis of the initial studies of ablation of b-secretase (BACE1) in APP-overexpressing mice that demonstrated abolished Ab generation and no detectable amyloid deposition (48) (49) (50) , inhibition of the enzymatic activity of BACE1 is considered to be one of the most promising targets for treating AD patients and developing BACE1 inhibitors as therapeutic agents is being energetically pursued. However, the development of b-secretase inhibitor was slowed down because of the difficulty in achieving adequate brain penetration (9) . In addition, newly identified BACE1 substrates and deeper analysis of BACE1 null mice that exhibited numerous subtle neuronal phenotypes suggest that complete abolishment of BACE1 activity may result in harmful phenotypical defects in memory processing, myelination and motor coordination (51) (52) (53) . Moreover, although multiple c-secretase inhibitors have been reported to reduce Ab production both in vitro and in vivo (54) (55) (56) (57) (58) (59) , and improve cognitive functioning in a transgenic mouse model of AD (60), active c-secretase inhibitors investigated in clinic but Phase III trial with semagacestat was prematurely halted in 2010 because of decline in cognition and increase risk of skin cancer (61) . Then, the c-secretase research has fallen into disgrace due to that failed c-secretase inhibitor Alzheimer's clinical trial led to abrupt closure of promising lines of c-secretase work (7). Therefore, the successful treatments that address the mechanism of modulation of either or both of these APP processing enzymes in Ab formation are urgent need. Our present findings suggest that blockade/inhibition of RAGE may offer a new approach to reduce Ab formation by modulating b-and c-secretase cleavage of APP to halt progression of AD.
In summary, the data presented herein clearly demonstrated, for the first time, that genetic deficiency of RAGE significantly reduced Ab accumulation in the brain by modulating b-and c-secretase activity through GSK-3b and p38 signaling pathway and improved spatial learning and memory in an AD mouse model. Our findings suggest that RAGE is a potential target to limit aberrant APP-Ab metabolism in halting progression of AD.
Materials and Methods
Generation and characterization of genetically modified mice
Transgenic mice with neuronal overexpression of a mutant human form of APP (Tg mAPP or mAPP, J-20 line, Jackson Lab) driven by the platelet-derived growth factor (PDGF) B-chain promoter were used in this study (30) . These mAPP mice are a wellestablished mouse model of AD and exhibit many features of AD neuropathology (19, 30) , and have been used in previously published studies (19, 20, (62) (63) (64) (65) . Homozygous RAGE null mice (29) (here termed as RO mice) were backcrossed into C57BL/6 strain for more than 12 generations, and were crossed with mAPP mice to generate mAPP/RO mice. The mAPP/DN-RAGE mice were produced in our laboratory as previously published (19) . Age-and sex-matched non-genetically modified WT littermates were used as controls in our studies. Mice were maintained on normal rodent chow and allowed free access to food and water at all times. Genomic DNA was isolated from tail biopsies and subjected to PCR analysis to identify the deficiency of RAGE or the presence of DN-RAGE or human APP gene.
The mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and flush perfused transcardially with 0.9% saline. Brains were removed and divided sagittally. One hemibrain was post-fixed in phosphate-buffered 4% paraformaldehyde (pH 7.4) at 4 C for 26 h and sectioned at 20 mm with a Vibratome (Leica); the other hemibrain was dissected to hippocampus and cortex, snap frozen and stored at -80 C for protein analysis and Ab ELISA. All animal studies were carried out with the approval of the Institutional Animal Care and Use Committee of Columbia University and University of Kansas.
Cell cultures
Rat neuroblastoma B103 cells stably expressing human WT APP were kindly provided by Tony Wyss-Coray (23). B103-wtAPP cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Catalog #10313021; Invitrogen/Thermo Fisher Scientific, Austin, TX, USA) containing 10% FBS, 5% heat inactivated horse serum, 500 lg/ml G418 (Catalog #11811023; Thermo Fisher Scientific, Austin, TX, USA). Cells were washed with serum free DMEM 24 h after planting and cultured in neurobasal medium containing 1% N-2 supplement (Catalog # 17502048, Thermo Fisher Scientific, Austin, TX, USA) to induce differentiation.
Transfection
B103-wtAPP cells were transfected with rat RAGE siRNA using siPORT Amine according to the manufacturer's pre-plate transfection procedure. Rat RAGE siRNA (Catalog #81722; ID s135582), negative control siRNA #4 (Catalog #AM4641) and siPORT Amine (Catalog #AM4641) were purchased from Applied Biosystems/Thermo Fisher Scientific (Austin, TX, USA). Briefly, cells were seeded on 6-well plates with normal growth medium so that they reached by 80% confluence after 24 h. SiPORT Amine agent was diluted into OPTI-MEM I medium (Catalog #11058021, Thermo Fisher Scientific) and incubated for 10 min at room temperature. Combine the diluted siPORT Amine with the diluted siRNA by pipetting up and down. Incubate 10 min at room temperature to allow transfection complexes to form. Mix the transfection complexes with cells and incubate at 37 C. Add equal amount of normal growth medium containing 20% FBS to the wells after 4 h. After 48 h, cells were harvested for RNA isolation using TRIZOL (Catalog #15596-018, Invitrogen/Thermo Fisher Scientific) or for protein expression analysis using lysis buffer.
Real-time quantitative PCR
Real-time quantitative PCR was performed as previously described (20) . Briefly, total RNA from transfected and nontransfected B103-wtAPP cells was isolated using TRIZOL and was processed directly to cDNA synthesis using the TaqMan reverse transcription reagents Kit (Catalog #N808-0234) from Applied Biosystems/Thermo Fisher Scientific (Austin, TX, USA) according to the manufacturer's protocol. Real-time PCR was performed using TaqMan Universal PCR Master Mix (Catalog #4304437, Applied Biosystems/Thermo Fisher Scientific, Austin, TX, USA). The rat RAGE (Catalog #4331182, ID #Rn00584249_m1) and ribosomal RNA (18s rRNA) probes and primers were purchased from Applied Biosystems/Thermo Fisher Scientific (Austin, TX, USA). Data are calculated using the 2 -DDCt method (66) and are presented as fold reduction of transcripts for target genes in RAGE siRNA transfected B103-wtAPP cells normalized to 18s rRNA, compared with control siRNA transfected B103-wtAPP cells (defined as 1.0-fold in each case). All reactions were performed in triplicate in ABI PRISM 7900HT Sequence Detection System. In vitro cleavage assay for assessment of b-and c-secretase activity 
Western blotting
ELISA
Ab ELISA analysis was performed to measure total human Ab40 and Ab42 levels in the brain tissue of the genetically modified mice and non-genetically modified WT littermates as previously described (19, (63) (64) (65) (67) (68) (69) 
Histochemical analyses
Serial vibratome sections (20 mm) were cut from 4% paraformaldehyde-fixed mice brains. Immunocytochemical analyses were performed using anti-Ab antibody 3D6 (dilution 1:1000, provided by Eli Lilly, Indianapolis, IN, USA) to identify Ab deposits. The area occupied by amyloid plaques in the entire hippocampus and cortex from the same level section in each animal group was determined by image analysis, using MetaMorph software from Universal Imaging Corporation (West Chester, PA).
Behavioral studies
Behavioral studies were performed to assess spatial learning and memory in the radial arm water maze as previously described (19) . The investigators were blinded to mouse genotypes until behavioral testing was completed.
Statistical analysis
All data are presented as means 6 SEM. Statistical comparisons between different groups were performed with ANOVA for repeated measure analysis using commercially available software (Statview, version 5.0.1, Berkeley, CA), followed by Fisher's protected least significant difference for post hoc comparisons. P 0.05 was considered significant.
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